(Bloomberg) — AC Immune, the Swiss developer of an Alzheimer’s treatment licensed to Roche Holding AG, will decide this year whether to pursue an initial public offering or a sale after Roche said it would start late-stage trials of the experimental drug.
AC Immune, backed by German billionaire Dietmar Hopp, will decide “in the next months” which route to take and doesn’t have a preference at the moment, Chief Executive Officer Andrea Pfeifer said in an interview on Wednesday.
The drugmaker is one of a string of companies weighing public sales in Switzerland, after Molecular Partners AG raised about 100 million Swiss francs ($104 million) last year, and Cassiopea Sp.A. went public this month.
“It seems to be really a perfect market to make this decision,” Pfeifer said. “We’re in an extremely solid financial situation and we will take our time.”